Literature DB >> 22247728

Visual acuity in an Iranian cohort of patients with type 2 diabetes: the role of nephropathy and ischemic heart disease.

Negar Horri1, Mahboube Farmani, Mahmoud Ghassami, Sassan Haghighi, Massoud Amini.   

Abstract

BACKGROUND: The aim of this study was to investigate the risk factors of low vision in type 2 diabetic patients and the prevalence of ischemic heart diseases and nephropathy for different visual acuities.
METHODS: In this cross-sectional study, data from 738 type 2 diabetic patients including evidences for nephropathy and ischemic heart disease, demographic characteristics, blood pressure and body mass index were collected, and then patients were divided into 3 groups based on their best corrected visual acuity in the better-seeing eye. Analysis of variance was used to compare basic characteristics according to different levels of visual acuity.
RESULTS: The prevalence of blindness and low vision was 5.5% and 13.3% respectively, and as age, duration of diabetes, systolic blood pressure and body mass index increased, the visual acuity decreased. The prevalence of hypertension and obesity in patients with visual disabilities was significantly higher than in patients with not impaired visions (p = 0.008 and p = 0.02, respectively). We also found that with greater decline in visual acuity, the prevalence of neph-ropathy and ischemic heart diseases increased.
CONCLUSIONS: The factors related to retinopathy play a role in affecting the degree of visual impairment in diabetic patients. Therefore, controlling risk factors can be useful in decreasing impairment of vision and blindness.

Entities:  

Keywords:  Blindness; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Nephropathies; Diabetic Retinopathy; Type 2; Visual Acuity

Year:  2011        PMID: 22247728      PMCID: PMC3252768     

Source DB:  PubMed          Journal:  J Res Med Sci        ISSN: 1735-1995            Impact factor:   1.852


Diabetes mellitus is one of the most common non-communicable diseases in the world. The WHO has predicted that, “the number of diabetic patients in the world will reach 300 millions by 2025, and more than 75% of these patients will be living in developing countries.1” Diabetic retinopathy is one of the most common complications of diabetes,2 and one of the leading causes of blindness and visual impairment.3–6 According to statistics from a decade ago, 40 million people were blind and 110 million had low vision.7 The American Diabetes Association claims that diabetes is responsible for 8% of legal blindness.8 Diabetic retinopathy and resulting blindness are responsible for a major disability in patients, and they lead to a high financial and social burden on the community indicating the importance of increased efforts in this field. Diabetic retinopathy is the principal cause of one-third of all cases of blindness,9 and also, according to some trials, a factor which is asso ciated to increased prevalence of cardiovascular diseases.10–12 These trials supposed that the pathogenesis of diabetic retinopathy and cardiovascular diseases are both microvascular. On the other hand, microalbuminuria which is another microvascular complication of diabetes has a connection with both, the development and progression of retinopathy.13 Taking into account the possibility that retinopathy, nephropathy and cardiovascular diseases may have similar pathogenesis in diabetic patients, and considering the role of retinopathy on vision acuity,14–16 it can be assumed that the prevalence of chronic complications of diabetes is different for different visual acuities, and risk factors related to diabetic retinopathy are possibly connected to visual impairment in diabetic patients. Since there are limited data on this field in Iran, and considering the fact that these data are essential for setting up of Iranian blindness prevention program, and also the clear effect of early screening and suitable intervention on reducing incidence of blindness and low vision related to diabetic retinopathy,1718 this study was performed in an Iranian population of type 2 diabetic patients at the Isfahan Endocrine and Metabolism Research Center with the aim of investigating our assumptions, and collecting as much information as possible concerning the prevalence of blindness and low vision and their related risk factors in our diabetic patients.

Methods

This cross-sectional study was conducted in April 2009, at the Endocrine and Metabolism Research Center of Isfahan University of Medical Sciences which covers 40% of diabetic patients of Isfahan. Study protocol was approved by the ethics committee of the center (Project No. 87015). The study complied with the current version of the Declaration of Helsinki. For this study we used routinely collected and registered data from patients registered at this center. These data were initially collected by an endocrinologist and subsequently via next follow-up visits to physicians at the center, and then the standard check lists that were filled out by these persons entered into the central computer system of the center. This information included: demographic characteristics, past history, family history, blood pressure, lipid profile, blood urea nitrogen (BUN), creatinin, HbA1c (glycosylated hemoglobin), urine albumin, the results of eye exams and of cardiovascular follow-ups. Lipid profile, BUN, creatinin, BP and body weight were usually monitored monthly and the ophthalmic, cardiovascular and renal condition of patients at least yearly. All lab tests were performed by the laboratory at the Endocrine and Metabolism Research Center. HbA1c was measured by spectrophotometer (DS5) and urine albumin by the sopt collection method. Creatinin was measured by the photometric method and albumin by the imunoturbidimetric method on a DB 3000 appliance.

Eye Examination

Eye examination was performed by an experienced ophthalmologist and included: testing of visual acuity (VA), corrected and uncorrected visual acuities were determined using a Snellen chart and a Canon autorefractometer (R-50m, Japan), best corrected visual acuity (BCVA) was defined as the visual acuity after subjective refraction in the better eye, and also intraocular pressure was measured using Goldman applanation tonometry (Haag-streit AG1A 900, Switzerland). The pupil of each eye was dilated using tropicamide 1% followed by a dilated fundus examination using a 78-dioptre non-contact fundus viewing lens (Volk). If needed, indirect ophthalmoscopy was performed. All findings were registered in special checklists.

Cardiac Condition Follow-Up

Ischemic heart disease was diagnosed by taking history and an ECG test. If there were electrocardiographic abnormalities as diagnosed by the Minesota-code or symptoms of ischemic heart disease,19 the patient was referred to a cardiologist for the exercise tolerance test and other diagnostic and therapeutic procedures.

Patients

Our target population was type 2 diabetic patients of Isfahan. As it has been mentioned before, the center covers 40% of diabetic patients of Isfahan. Between 2008 and 2009, 1300 diabetic patients came to the center for their follow-up visits. Of these patients, 1000 persons had type 2 diabetes and 300 persons had type 1. For this study we used data collected from 900 conveniently-selected patients with type 2 diabetes who had a complete eye exam during that period. Patients with incomplete records on their ophthalmologic exam or on evidences of nephropathy and ischemic heart disease were excluded from the study

Definitions

The patients were divided into 3 groups based on their best corrected visual acuity (BCVA) in the better seeing eye, using the North American definition.20 Best Corrected Visual Acuity: Not impaired was defined as best corrected visual acuity better than or equal to 20/40 (5/10), low vision as worse than 20/40 but better than 20/200 (2/10-4/10) and blind was defined as 2/200 or worse (1/10 or worse). Ischemic Heart Disease: The patients who have been put on treatment or undergone surgery like coronary artery bypass graft (CABG) surgery or percutaneous transluminal coronary angioplasty (PTCA) after diagnostic tests Nephropathy: Urine albumin/creatinin more than 30mg/g21 Hypertension: (in diabetic patients) Systolic/diastolic blood pressure ≥ 130/80 mmHg22 Obesity: Body mass index (weight in kg/squared of height in m) ≥ 30 kg/m23

Statistical Analysis

We used t-test to compare continuous variables, chi-square test to compare categorical variables, and analysis of variance (ANOVA) test to compare basic characteristics according to different levels of visual acuity. In all instances, p values < 0.05 were considered significant. Data analyses were done using the SPSS version 13 (Chicago, USA).

Results

Of the 900 investigated files, 162 were excluded because of incomplete information. The study included data from 738 patients. Of these patients with the mean age of 60.29 ± 10.3 years, 41 patients (5.5%) were blind (95% Confidence Interval (CI): 2.5-13.2) and 98 patients (13.3%) had low vision, (95% CI: 4.3-32.3). Tables 1 and 2 show the demographic characteristics for patients divided into 3 groups and results of post hoc tests for continuous variables among 3 groups of patients with different visual acuities, respectively. According to these data, there was a significant difference among 3 groups in terms of mean age, body mass index (BMI), duration of diabetes and systolic blood pressure. Presence of any of the following conditions was associated with corresponding decrease in visual acuity: increasing age, longer duration of diabetes, higher systolic blood pressure, and increased body mass index.
Table 1

Basic clinical and demographic characteristics and mean of HbA1c of patients with different visual acuities

Table 2

Results of post hoc tests for basic clinical and demographic characteristics and mean of HbA1c among 3 groups of patients with different visual acuities

Basic clinical and demographic characteristics and mean of HbA1c of patients with different visual acuities Results of post hoc tests for basic clinical and demographic characteristics and mean of HbA1c among 3 groups of patients with different visual acuities Table 3 shows the prevalence of different levels of visual acuity by the presence of hypertension or obesity. According to this table, when patients in blind and low vision groups are considered together, it is evident that 20.3% of hypertensive patients and 5.5% of non-hypertensive ones have visual disability (p = 0.008), and 22.9% of obese patients and 16.2% of non-obese ones have visual impairment (p = 0.02).
Table 3

Prevalence of different levels of visual acuity in type 2 diabetic patients with and without hypertension or obesity

Prevalence of different levels of visual acuity in type 2 diabetic patients with and without hypertension or obesity Table 4 shows the prevalence of ischemic heart diseases (IHD) and nephropathy in 3 groups.
Table 4

Prevalence of ischemic heart disease and nephropathy in 3 groups of type 2 diabetic patients with different levels of visual acuity

Prevalence of ischemic heart disease and nephropathy in 3 groups of type 2 diabetic patients with different levels of visual acuity Considering these data, there is a significant difference between the 3 groups in terms of the prevalence of IHD and nephropathy. The prevalence of nephropathy is significantly higher in the group with blindness than in both groups with not impaired vision (p = 0.003) and those with low vision (p = 0.01). Also the prevalence of IHD was significantly lower in patients with not impaired vision than those with visual disabilities.

Discussion

In this cross-sectional study carried out on 738 registered type 2 diabetic patients, the prevalence of blindness and low vision was 5.5% and 13.3%, respectively. It was observed that the visual acuity decreased with increasing age, duration of diabetes, systolic blood pressure, and body mass index. It was also showed that with greater decline in visual acuity, the prevalence of nephropathy and ischemic heart diseases increased. Reported prevalence of blindness and low vision is very different in various societies. The prevalence of blindness in type 2 diabetic patients in Yemen was 16%,24 in Taiwan was 1.6%,25 in Denmark was 1.5%26 and in England was 1.16%.27 It has been claimed by the Center for Disease Control that among adults with diabetes, 2.9% suffered from mild vision impairment and 1% had severe visual impairment after correction.28 One reason for the higher prevalence of visual impairment and blindness in our study in comparison with other studies was the nature and the type of groups studied. The Taiwan study was a population-based diabetic retinopathy screening program. The study in England was a population-based study of diabetic patients in a district in the northwest of England. The Denmark study included blind cases registered in a database of diabetic patients, but our study has been carried out at a referral center for diabetic patients, which is affiliated to Isfahan University of Medical Sciences, and the prevalence of each chronic complication may be affected by this referral pattern, because the number of patients with more severe complications is greater, they also make more frequent visits and are more vigilant. Other possible reasons for high prevalence of low vision and blindness in our study was primarily the long duration of diabetes (more than 15 years in 30.5%) and secondly, high prevalence of hypertension and nephropathy (89.8% and 83% respectively) in our studied population. Different studies claimed that, the duration of diabetes,29–31 age,2932 high blood pressure,33–35 and albuminuria,1427 are directly related to the onset and progression of diabetic retinopathy, and diabetic retinopathy is one of the major causes of visual impairment in diabetic patients,1336 so it is reasonable to suppose that risk factors related to it are also related to the status of visual acuity. The results of our research revealed that our supposition was well-founded, and age, duration of diabetes, body mass index and systolic blood pressure were also related to the severity of visual impairment. In addition, in our study, hypertension and obesity were significantly more prevalent in patients with visual disabilities than in patients with unimpaired visions. Some other trials have also shown that there is a relationship between systolic blood pressure and diabetic retinopathy,32 and have claimed that the severity of retinopathy in type 2 diabetic patients is positively associated with systolic blood pressure28 and body mass index.34 In our study there was no relationship between different levels of visual acuity and sex. In an independent study in Isfahan, Janghorbani et al also reached the conclusion that there was no association between retinopathy and sex,32 which was in agreement with the results of other studies.2433 We also found a relationship between severity of visual impairment and prevalence of ischemic heart disease and nephropathy. In the Ossama et al study, there was also a relationship between ischemic heart disease and retinopathy, but after adjustment for risk factors, the relationship was no longer significant.33 A limited number of studied ischemic heart disease cases (44/500) was mentioned as the possible reason for this finding, but in our study, the number of ischemic heart disease cases was not limited (Table 4); so, it seems that the prevalence of ischemic heart disease does not have an independent relationship with visual acuity. The reason is possibly the difference in pathogenesis of ischemic heart disease and retinopathy; the former is macro-vascular in nature and the latter has a micro-vascular pattern. Nephropathy, which was in direct relationship with visual acuity has also a microvascular basis. We are fortunate at our center to have access to some of the most comprehensive data of its kind in the developing world. Based upon information from earlier studies, it is clear that our patients are a representative sample of known diabetics in Isfahan.3237 In addition, a positive aspect of our diagnosis of ischemic heart disease, nephropathy, hypertension and obesity was that it has not been based on a single examination but on continued examinations during follow-ups. However, this study has also some limitations. The study was of course clinic-based rather than population-based. Clinic-based estimates of the prevalence of complications are most likely to be affected by referral patterns, since patients at our clinic are more likely to have complications, and it has been showed by experience that once a complication occurs, patients are more likely to come regularly for treatment, and this factor affects the estimated prevalence of complications. Considering the above-mentioned reasons, it seems that a population-based study will be needed regarding the matter in the future.

Conclusion

The factors related to retinopathy play a role in affecting the degree of visual impairment in diabetic patients. Considering the fact that the high prevalence of low vision is a serious threat to the health of diabetic patients in Isfahan, control of risk factors can be useful in decreasing impairment of vision and blindness.

Authors’ Contributions

NH was the principal investigator of the research project, carried out the design, coordinated the study, participated in all of the research stages, and also in manuscript preparation. MF assisted in designing the study and coordinated and assisted in carrying out all the research stages. MG assisted in designing the study and assisted in carrying out the research. SH assisted in designing the study, coordinated in carrying out the research, and participated in manuscript preparation and revision. MA assisted principally in designing the study and participated in manuscript preparation and revision.
  33 in total

Review 1.  Screening and prevention of diabetic blindness.

Authors:  E Stefánsson; T Bek; M Porta; N Larsen; J K Kristinsson; E Agardh
Journal:  Acta Ophthalmol Scand       Date:  2000-08

Review 2.  Prevention of diabetic renal disease with special reference to microalbuminuria.

Authors:  C E Mogensen; W F Keane; P H Bennett; G Jerums; H H Parving; P Passa; M W Steffes; G E Striker; G C Viberti
Journal:  Lancet       Date:  1995-10-21       Impact factor: 79.321

3.  The prevalence of low vision and blindness in a Canadian inner city.

Authors:  D A L Maberley; H Hollands; A Chang; S Adilman; B Chakraborti; G Kliever
Journal:  Eye (Lond)       Date:  2006-02-03       Impact factor: 3.775

4.  Diabetic retinopathy and the risk of coronary heart disease: the Atherosclerosis Risk in Communities Study.

Authors:  Ning Cheung; Jie Jin Wang; Ronald Klein; David J Couper; A Richey Sharrett; Tien Y Wong
Journal:  Diabetes Care       Date:  2007-03-26       Impact factor: 19.112

5.  Diabetic retinopathy. American Diabetes Association.

Authors: 
Journal:  Diabetes Care       Date:  1998-01       Impact factor: 19.112

6.  Prevalence and risk factors for retinopathy in adolescents with type 1 diabetes.

Authors:  J M Fairchild; S J Hing; K C Donaghue; M A Bonney; A T Fung; M M Stephens; P Mitchell; N J Howard; M Silink
Journal:  Med J Aust       Date:  1994-06-20       Impact factor: 7.738

7.  Blood pressure, lipids, and obesity are associated with retinopathy: the hoorn study.

Authors:  Hendrik A van Leiden; Jacqueline M Dekker; Annette C Moll; Giel Nijpels; Robert J Heine; Lex M Bouter; Coen D A Stehouwer; Bettine C P Polak
Journal:  Diabetes Care       Date:  2002-08       Impact factor: 19.112

8.  Diabetic retinopathy is associated with an increased incidence of cardiovascular events in Type 2 diabetic patients.

Authors:  G Targher; L Bertolini; L Zenari; G Lippi; I Pichiri; G Zoppini; M Muggeo; G Arcaro
Journal:  Diabet Med       Date:  2008-01       Impact factor: 4.359

9.  Preventive eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform.

Authors:  J C Javitt; L P Aiello; Y Chiang; F L Ferris; J K Canner; S Greenfield
Journal:  Diabetes Care       Date:  1994-08       Impact factor: 19.112

10.  Executive summary: standards of medical care in diabetes--2009.

Authors: 
Journal:  Diabetes Care       Date:  2009-01       Impact factor: 19.112

View more
  5 in total

1.  Using skew-symmetric mixed models for investigating the effect of different diabetic macular edema treatments by analyzing central macular thickness and visual acuity responses.

Authors:  Marjan Mansourian; Anoshirvan Kazemnejad; Iraj Kazemi; Farid Zayeri; Masoud Soheilian
Journal:  J Res Med Sci       Date:  2011-10       Impact factor: 1.852

2.  The effects of soy bean flour enriched bread intake on anthropometric indices and blood pressure in type 2 diabetic women: a crossover randomized controlled clinical trial.

Authors:  Asma Salari Moghaddam; Mohammad Hassan Entezari; Bijan Iraj; Gholamreza Askari; Elham Sharifi Zahabi; Mohammad Reza Maracy
Journal:  Int J Endocrinol       Date:  2014-09-08       Impact factor: 3.257

3.  The Effects of Consumption of Bread Fortified With Soy Bean Flour on Metabolic Profile in Type 2 Diabetic Women: A Cross-over Randomized Controlled Clinical Trial.

Authors:  Asma Salari Moghaddam; Mohammad Hassan Entezari; Bijan Iraj; Gholam Reza Askari; Mohammad Reza Maracy
Journal:  Int J Prev Med       Date:  2014-12

4.  The Association of Visual Impairment With Clinical Outcomes in Hemodialysis Patients.

Authors:  Yu Ah Hong; Suk Young Kim; Su-Hyun Kim; Young Ok Kim; Dong Chan Jin; Ho Chul Song; Euy Jin Choi; Yong-Lim Kim; Yon-Su Kim; Shin-Wook Kang; Nam-Ho Kim; Chul Woo Yang; Yong Kyun Kim
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

5.  Risk factors for visual impairment and blindness amongst black adult diabetics receiving treatment at Government healthcare facilities in Mopani District, Limpopo province, South Africa.

Authors:  Raymond G Mabaso; Olalekan A Oduntan
Journal:  Afr J Prim Health Care Fam Med       Date:  2014-11-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.